Clinical Trials Study
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2014; 20(25): 8215-8220
Published online Jul 7, 2014. doi: 10.3748/wjg.v20.i25.8215
Mesenchymal stem cell therapy in patients with small bowel transplantation: Single center experience
Sait Murat Doğan, Selçuk Kılınç, Eyüp Kebapçı, Cem Tuğmen, Alp Gürkan, Maşallah Baran, Yusuf Kurtulmuş, Mustafa Ölmez, Cezmi Karaca
Sait Murat Doğan, Selçuk Kılınç, Eyüp Kebapçı, Cem Tuğmen, Mustafa Ölmez, Cezmi Karaca, Organ Transplantation Center, SB Tepecik Teaching and Research Hospital, 35121 Izmir, Turkey
Alp Gürkan, Organ Transplantation Center, Camlıca University Hospital, 34360 Istanbul, Turkey
Maşallah Baran, Department of Gastroenterology, SB Tepecik Teaching and Research Hospital, 35121 Izmir, Turkey
Yusuf Kurtulmuş, Tissue Typing Laboratory, SB Tepecik Teaching and Research Hospital, 35121 Izmir, Turkey
Author contributions: Dogan SM designed and performed the study, collected the data and wrote the paper; Kılınç S and Kebapçı E designed and performed the study, collected the data; Tuğmen C, Karaca C and Ölmez M performed the study and collected the data; Gürkan A analyzed the study, wrote and revised the paper; Baran M and Kurtulmuş Y collected the data.
Correspondence to: Alp Gürkan, MD, Organ Transplantation Center, Camlıca University Hospital, Burhaniye Mah, Yunus Emre Sok 18, 34360 Istanbul, Turkey. alpgurkan1@gmail.com
Telephone: +90-532-2667938 Fax: +90-532-2667938
Received: December 25, 2013
Revised: February 9, 2014
Accepted: April 2, 2014
Published online: July 7, 2014
Processing time: 191 Days and 11 Hours
Abstract

AIM: To study the effects of mesenchymal stem cell (MSC) therapy on the prevention of acute rejection and graft vs host disease following small bowel transplantation.

METHODS: In our transplantation center, 6 isolated intestinal transplants have been performed with MSC therapy since 2009. The primary reasons for transplants were short gut syndrome caused by surgical intestine resection for superior mesenteric artery thrombosis (n = 4), Crohn’s disease (n = 1) and intestinal aganglionosis (n = 1). Two of the patients were children. At the time of reperfusion, the first dose of MSCs cultured from the patient’s bone marrow was passed into the transplanted intestinal artery at a dose of 1000000 cells/kg. The second and third doses of MSCs were given directly into the mesenteric artery through the arterial anastomosis using an angiography catheter on day 15 and 30 post-transplant.

RESULTS: The median follow-up for these patients was 10.6 mo (min: 2 mo-max: 30 mo). Three of the patients developed severe acute rejection. One of these patients did not respond to bolus steroid therapy. Although the other two patients did respond to anti-rejection treatment, they developed severe fungal and bacterial infections. All of these patients died in the 2nd and 3rd months post-transplant due to sepsis. The remaining patients who did not have acute rejection had good quality of life with no complications observed during the follow-up period. In addition, their intestinal grafts were functioning properly in the 13th, 25th and 30th month post-transplant. The patients who survived did not encounter any problems related to MSC transplantation.

CONCLUSION: Although this is a small case series and not a randomized study, it is our opinion that small bowel transplantation is an effective treatment for intestinal failure, and MSC therapy may help to prevent acute rejection and graft vs host disease following intestinal transplantation.

Keywords: Short gut syndrome; Small bowel transplantation; Mesenchymal stem cells; Acute rejection; Stem cell therapy

Core tip: Intestinal transplantation significantly improves prognosis and increases quality of life in patients with short gut syndrome. Transplantation of mesenchymal stem cells (MSCs) has been studied recently in animal models and in clinical trials of patients with hepatic failure, end-stage liver disease and inherited metabolic disorders. However, studies and data related to MSC therapy in small bowel transplantation are scarce. We think that MSC therapy may help to prevent acute rejection and graft vs host disease following intestinal transplantation.